Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 16/20 | 0.41 |
| ▸ | PIM1 | P11309 | 8/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979931 | 0.99 | TLR8 (0.55) | TLR8TLR7NCF1PIM2PIM1 | |
| SCHEMBL18991680 | 0.99 | TLR8 (0.55) | TLR8TLR7NCF1PIM2PIM1 | |
| Trifluoroacetic Acid SCHEMBL21645190 | 0.92 | TLR7 (0.52) | TLR8TLR7NCF1PIM2PIM1 | |
| Hydrochloric Acid SCHEMBL21645218 | 0.88 | TLR8 (0.70) | TLR8TLR7NCF1PIM2PIM1 | |
| SCHEMBL21645323 | 0.86 | TLR8 (0.72) | TLR8TLR7NCF1PIM2PIM1 | |
| Hydrochloric Acid SCHEMBL18980063 | 0.86 | TLR8 (0.51) | TLR8PIM2PIM1PIM3KCNH2 | |
| Hydrochloric Acid SCHEMBL23855279 | 0.86 | PIM2 (0.42) | TLR8TLR7PIM2PIM1PIM3 | |
| SCHEMBL18980683 | 0.85 | TLR8 (0.53) | TLR8TLR7NCF1PIM2CTSB | |
| SCHEMBL18980680 | 0.85 | TLR8 (0.53) | TLR8TLR7NCF1PIM2CTSB | |
| SCHEMBL18980682 | 0.85 | TLR8 (0.53) | TLR8TLR7NCF1PIM2CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| CN-108699032-B | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3889145-A1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-01-28 | — | — | US | disclosed |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | KCNH2 4018/4885TLR8 2/4885TLR7 1/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KCNH2 4018/4885TLR8 2/4885TLR7 1/4885 |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | KCNH2 4302/4885TLR8 2/4885TLR7 1/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KCNH2 4070/4885TLR8 2/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.